KENNEWICK, WA – May 11, 2026 – Vivos Inc. (OTCQB: RDGL) is pleased to provide the following update regarding its latest study on IsoPet® Postoperative Precision Radionuclide Therapy™ (PRnT).
Initial clinical data from the study highlight the feasibility, safety, and promise of IsoPet® Precision Radionuclide Therapy™ (PRnT) as a novel postoperative treatment for incomplete histologic margins in veterinary oncology.
IsoPet® (Vivos Inc.), a Y-90 phosphate hydrogel for Precision Radionuclide Therapy™ (PRnT), enables direct interstitial injection for localized high-dose beta radiation with rapid dose fall-off, minimizing exposure to adjacent healthy tissues.
Vivos Inc. announces the successful completion of patient enrollment in its 20-patient prospective clinical evaluation of the company’s IsoPet® Postoperative Precision Radionuclide Therapy for Treatment of Incomplete Histologic Margins protocol. This innovative postoperative application of IsoPet® Precision Radionuclide Therapy™ (PRnT) is designed to treat microscopic residual cancer following incomplete tumor excision in veterinary patients. Local recurrence after incomplete tumor resection is a primary cause of surgical treatment failure in veterinary oncologic surgery, especially for neoplasms where wide excisional margins compromise function or are anatomically challenging.
The abstract, titled “Postoperative Precision Radionuclide Brachytherapy for Incomplete Tumor
Resection,” has been prepared for submission to the American College of Veterinary Surgeons (ACVS) Surgical Summit for consideration as an oral presentation.
The study evaluated postoperative IsoPet® treatment in 20 client-owned veterinary patients, including 17 canines and 3 felines, with histologically confirmed incomplete surgical margins following tumor resection. Tumor types included soft tissue sarcomas, squamous cell carcinomas, mast cell tumors, and carcinomas.
Using a standardized grid-pattern injection protocol, IsoPet® Y-90 hydrogel was administered directly along the surgical scar line and lateral margins to deliver targeted ablative radiation doses intended to sterilize microscopic residual disease while minimizing radiation exposure to surrounding healthy tissues. Animals are being monitored for adverse events (AEs) at 2 weeks and at 1, 3, and 6 months.
Key preliminary findings from the study include:
- Successful treatment delivery in all 20 cases with no procedural or device-related complications.
- No Grade 3 or higher acute adverse events observed.
- Only one patient experienced mild, transient Grade 1–2 erythema and edema that resolved without intervention.
- Median follow-up of 4 months (range 1–6 months).
- No local regrowth has been identified in 12 cases to date.
- Eight recurrent cases underwent successful retreatment with no signs of recurrence observed following retreatment.
Traditional postoperative radiation therapy in veterinary medicine often requires multiple anesthetic events, repeated hospital visits, specialized radiation facilities, and may expose surrounding tissues to unintended toxicity. IsoPet® PRnT is designed to provide localized beta radiation with rapid dose falloff, potentially reducing morbidity, logistical burden, and overall treatment complexity.
“This study represents an important milestone in the advancement of the IsoPet® Postoperative treatment for incomplete histologic margins,” said Brad Weeks, President of Vivos. “We are incredibly encouraged by the early safety profile and clinical feasibility demonstrated in these initial cases and look forward to continued collaboration with leading veterinary surgeons and oncologists.”
These encouraging clinical results are already driving strong commercial momentum. Vivos Inc. is pleased to report increasing IsoPet® adoption across multiple certified clinic locations as veterinarians observe the clear benefits of this advanced Precision Radionuclide Therapy™ technology in real-world practice. The company is also experiencing rising revenue, is narrowing the gap toward IsoPet® profitability, and anticipates matching or exceeding its full-year 2025 revenue during the first half of 2026. In addition, Vivos is preparing to bring online its new in-house production facility, which is expected to deliver significant improvements in manufacturing efficiency and support scaled treatment of a growing number of patients.
Vivos Inc. plans to further expand clinical investigation of IsoPet® Postoperative protocols through additional studies currently being evaluated at the same clinical site. The company plans future peer-reviewed publications arising from the growing body of clinical data generated through these studies.
About Vivos Inc.
Vivos Inc. is advancing next-generation Precision Radionuclide Therapy™ (PRnT) platforms designed to deliver highly targeted cancer treatment directly to tumors and surgical margins while minimizing exposure to surrounding healthy tissue. Through its proprietary technologies, RadioGel® for human applications and IsoPet® for veterinary oncology, Vivos is developing innovative minimally invasive therapies aimed at improving treatment precision, patient outcomes, and accessibility in both human and animal cancer care. RadioGel® is currently not approved for human applications in the United States.
Contact:
Mike Korenko, ScD
CEO, Vivos Inc.
mkorenko@radiogel.com
Brad Weeks
President, Vivos Inc.
brad.weeks@vivosinc.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
